Therefore, our results suggest that, in addition to amplification of EGFR, lung cancers can also adopt homozygous deletions of CPEB3 as an alternative mechanism to overexpress EGFR. This raises the possibility that EGFR-targeted therapy may also be effective in patients with homozygous deletions of CPEB3. Here, EGFR is linked to lung carcinoma.